Arcuro Medical awarded US FDA regulatory clearance for SuperBall for the preservation of knee functionality.
M2 EQUITYBITES-June 19, 2018-Arcuro Medical awarded US FDA regulatory clearance for SuperBall for the preservation of knee functionality
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Arcuro Medical Ltd said on Monday that it has received regulatory clearance from the US Food and Drug Administration (FDA) for its SuperBall meniscus repair system for the preservation of knee functionality.
Meniscus tears are a common occurrence in professional athletes, people who engage in daily sport activities, the ageing population and people predisposed to cartilage problems. The current practice seeks to avoid removal of the meniscus and prefers arthroscopic repair techniques.
In conjunction with the US FDA approval, the company has developed an all-suture meniscus repair system that preserves knee functionality and is secure, reliable and effective. It has completed an extensive and very successful series of pre-clinical studies in the US and Israel.
Utilising the company's easy-to-use system, an all-suture implant, with no knot in the joint space, more surgeons will choose to repair the meniscus instead of removing it. As a result, Arcuro expects to convert a significant portion of the meniscus removal procedures performed annually to repair procedures.
Additionally, the company has submitted a patent at national phase in China, Israel, the US and Europe. The patent in the US was recently granted.
Arcuro Medical Ltd develops meniscus repair system for anatomic repair of joints and is a portfolio company of The Trendlines Group Ltd (SGX:42T) (OTCQX:TRNLY).
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jun 19, 2018|
|Previous Article:||JMP Group adds Carin Fradin as managing director for its investment banking division.|
|Next Article:||Insight Select Income Fund announces dividend of USD0.20 per share for quarter.|